Global Anti-CD19 Therapeutic Antibody Market, By Application (Malignancies, Autoimmune Diseases and Others), Drug Class (Antibody Drug Conjugates, (CAR) T-Cell Therapy, Engineered Antibodies and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Anti-CD19 Therapeutic Antibody Market
Global anti-CD19 therapeutic antibody market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned forecast period. Factors such as growing prevalence of acute leukemia cases and autoimmune diseases are responsible for the growth of anti-CD19 therapeutic antibody market globally. Moreover, increasing number of research grants and activities in this field can also boost the growth of this market.
CD19 is an antigen, which belongs to the class of immunoglobulins. It has been recognized as a biomarker for normal and neoplastic B cells, as well as for follicular dendritic cells. CD19 is considered as potential target for many monoclonal antibodies. A number of new anti-CD19 therapeutics like KTE-C19, CTL019 and others are under pipeline. However, lack of awareness and perfection about the use of anti-CD19 therapeutic antibody, rise in cost of treatment and side effects associated with treatment, can restrain the growth of this market.
This anti-CD19 therapeutic antibody market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Anti-CD19 Therapeutic Antibody Market Scope and Market Sizes
Anti-CD19 therapeutic antibody market is segmented on the basis of application, drug class, end-users and distribution channel. The growth amongst the different segments helps you in attaining the knowledge related to the different growth factors expected to be prevalent throughout the market and formulate different strategies to help identify core application areas and the difference in your target markets.
- On the basis of application, the anti-CD19 therapeutic antibody market is segmented into malignancies, autoimmune diseases and others.
- On the basis of drug class, the anti-CD19 therapeutic antibody market is segmented into antibody drug conjugates, chimeric antigen receptor (CAR) T-Cell therapies, engineered antibodies and others.
- On the basis of end-users, the anti-CD19 therapeutic antibody market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the anti-CD19 therapeutic antibody market has also been segmented into hospital pharmacy, retail pharmacy and others.
Anti-CD19 Therapeutic Antibody Market Country Level Analysis
Anti-CD19 therapeutic antibody market is analyzed and market size information is provided by country, application, drug types, end-users and distribution channel as referenced above.
The countries covered in the anti-CD19 therapeutic antibody market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
Asia-Pacific is expected to account for the largest market share over coming years for anti-CD19 therapeutic antibody market due to increasing prevalence of malignancies, Europe is considered to hold bright growth prospects in the coming years while North America is considered to lead the growth due to the focus of global players on novel technology.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Anti-CD19 therapeutic antibody market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Anti-CD19 Therapeutic Antibody Market Share Analysis
Anti-CD19 therapeutic antibody market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to anti-CD19 therapeutic antibody market.
The major players covered in anti-CD19 therapeutic antibody market are Amgen Inc, Sanofi, AstraZeneca, Morphosys AG, Xencor, Inc, Seattle Genetics, Inc., Bristol-Myers Squibb Company, Affimed GmbH, Bio-Rad Laboratories, Inc., Bayer AG, Bellicum Phamaceuticals, Inc., Cellular Biomedicine Group among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-